AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
News|Articles|April 14, 2026
A New Era of Fairness and Transparency in PBM-Pharmacist Relationships
Author(s)Brian Nowosielski
Chad Worz, PharmD, BCGP, FASCP, and Jeffrey Hogan, present on the implications behind major PBM reform signed in February and how the reimbursement landscape is expected to shift.
Advertisement
Advertisement
The landscape of pharmacy benefit management is undergoing a structural transformation that promises to redefine the financial and operational reality for pharmacists across the US.
Related to this article
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.
Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.
Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.
Advertisement
Advertisement